UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
27.04
+0.19 (0.71%)
Jun 8, 2026, 11:34 AM EDT - Market open
UroGen Pharma Employees
UroGen Pharma had 298 employees as of March 31, 2026. The number of employees increased by 64 or 27.35% compared to the same quarter last year.
Employees
298
Change
64
Growth
27.35%
Revenue / Employee
$471,453
Profits / Employee
-$447,064
Market Cap
1.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 298 | 64 | 27.35% | 298 | 0 |
| Dec 31, 2025 | 291 | 56 | 23.83% | 291 | 0 |
| Sep 30, 2025 | 287 | 70 | 32.26% | 287 | 0 |
| Jun 30, 2025 | 253 | 50 | 24.63% | 253 | 0 |
| Mar 31, 2025 | 234 | 30 | 14.71% | 234 | 0 |
| Dec 31, 2024 | 235 | 34 | 16.92% | 235 | 0 |
| Sep 30, 2024 | 217 | 25 | 13.02% | 217 | 0 |
| Jun 30, 2024 | 203 | 10 | 5.18% | 203 | 0 |
| Mar 31, 2024 | 204 | 10 | 5.15% | 204 | 0 |
| Dec 31, 2023 | 201 | 1 | 0.50% | 198 | 3 |
| Sep 30, 2023 | 192 | -3 | -1.54% | 192 | 0 |
| Jun 30, 2023 | 193 | -8 | -3.98% | 193 | 0 |
| Mar 31, 2023 | 194 | 2 | 1.04% | 194 | 0 |
| Dec 31, 2022 | 200 | 5 | 2.56% | 200 | 0 |
| Sep 30, 2022 | 195 | -3 | -1.52% | 195 | 0 |
| Jun 30, 2022 | 201 | 11 | 5.79% | 201 | 0 |
| Mar 31, 2022 | 192 | 2 | 1.05% | 192 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| Ardelyx | 489 |
| Maravai LifeSciences Holdings | 416 |
| Precigen | 160 |
| Maze Therapeutics | 141 |
| MapLight Therapeutics | 133 |
| MoonLake Immunotherapeutics | 130 |
| Inhibrx Biosciences | 110 |
URGN News
- 3 days ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution - GlobeNewsWire
- 6 days ago - UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 13 days ago - UroGen Pharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 20 days ago - UroGen Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 24 days ago - UroGen Pharma reports month results from UTOPIA trial - TheFly
- 24 days ago - UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC - GlobeNewsWire
- 26 days ago - UroGen Pharma Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts